A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older.

Trial Profile

A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Darifenacin; Tolterodine
  • Indications Overactive bladder
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Results have been presented at the 39th Annual Meeting of the International Continence Society.
    • 17 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top